← Eichor
Study identifier: NCT06478537 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

Condition: Immune Thrombocytopenia  ·  Sponsor: Peking Union Medical College Hospital

PhasePhase 2
Planned participants56
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersNo

About this study

The aim of this study was to observe whether maintaining a high level of platelet count after TPO-RA in patients with primary immune thrombocytopenia (ITP) can induce immune tolerance, develop immune balance in ITP patients, and enable patients to achieve a sustained response (SRoT) after TPO-RA discontinuation.

This description comes directly from the study's public registry record.

Talk to the study team

Tienan Zhu, M.D.  ·  01069155027  ·  zhutn@pumch.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06478537